ASH 2022 | Feasibility of FMT to prevent acute GvHD after alloHSCT & restore gut microbiota diversity

Florent Malard • 21 Nov 2022

ASH 2022

General

Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, comments on the feasibility of fecal microbiota transplantation (FMT) as a strategy to prevent and treat acute graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (alloHSCT). Dr Malard emphasizes that this field of research is completely investigational, with no current therapies or agents known to improve the gut microbiome after alloHSCT. Dr Malard outlines preliminary results of a study that investigated the efficacy of FMT after alloHSCT, in hopes to restore microbiota diversity. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Therakos/Mallinckrodt: Honoraria; Sanofi: Honoraria; Astellas: Honoraria; JAZZ pharmaceuticals: Honoraria; Biocodex: Honoraria; Janssen: Honoraria; Takeda: Honoraria; Novartis: Honoraria; Gilead: Honoraria; Celgene-BMS: Honoraria.